Mylan to buy Agila of India for $1.6 billion

  • February 28, 2013

CANONSBURG (AP) — Generic drug maker Mylan Inc. says it will buy Agila Specialties for $1.6 billion in cash, expanding its offerings of injectable drugs and its sales in international markets.

Southpointe-based Mylan is buying Agila from Strides Arcolab. It could pay Strides another $250 million based on other undisclosed conditions. Mylan said the deal will give it new generic injectable drugs and will help it enter the market in emerging markets like Brazil.

Mylan expects the Agila purchase will add to its earnings. The transaction is expected to close in the fourth quarter.

Both Agila and Strides are based in India.

Mylan is one of the biggest generic drug companies in the world. Its sales grew 11 percent to $6.8 billion in 2012.


blog comments powered by Disqus

Markets fade after an early gain, finish with small losses

Home sales slump in Oct. as higher prices weigh on buyers

Pfizer, Allergan $160B deal forms world’s largest drugmaker

North Franklin woman uses art to help nonprofits while dealing with cystic fibrosis

Small talk: Obstacles, prejudice being overcome by deaf business owners

U.S. home rental prices rise at slower pace in October

Rig count declines by 10 this week to 757

New still added as part of Maker’s Mark expansion

Aetna, Anthem reassure investors on forecast, exchanges

Mylan acquisiton broadens women’s health care portfolio